Shah Nikita 4
4 · Amneal Pharmaceuticals, Inc. · Filed Mar 5, 2026
Insider Transaction Report
Form 4
Shah Nikita
Executive Vice President
Transactions
- Exercise/Conversion
Class A Common Stock
[F1][F2]2026-03-03+36,232→ 182,635 total - Tax Payment
Class A Common Stock
[F3]2026-03-03$13.31/sh−18,502$246,262→ 164,133 total - Exercise/Conversion
Class A Common Stock
[F1][F2]2026-03-03+45,871→ 210,004 total - Tax Payment
Class A Common Stock
[F3]2026-03-03$13.31/sh−22,982$305,890→ 187,022 total - Exercise/Conversion
Class A Common Stock
[F1][F2]2026-03-03+23,544→ 210,566 total - Tax Payment
Class A Common Stock
[F3]2026-03-03$13.31/sh−11,796$157,005→ 198,770 total - Exercise/Conversion
Class A Common Stock
[F4]2026-03-03+366,972→ 565,742 total - Tax Payment
Class A Common Stock
[F5]2026-03-03$13.31/sh−183,853$2,447,083→ 381,889 total - Exercise/Conversion
Class A Common Stock
[F1][F2]2026-03-04+35,880→ 417,769 total - Tax Payment
Class A Common Stock
[F3]2026-03-04$13.30/sh−17,976$239,081→ 399,793 total - Exercise/Conversion
Restricted Stock Units
[F2][F6]2026-03-03−36,232→ 0 total→ Class A Common Stock (36,232 underlying) - Exercise/Conversion
Restricted Stock Units
[F2][F7]2026-03-03−45,871→ 45,872 total→ Class A Common Stock (45,871 underlying) - Exercise/Conversion
Restricted Stock Units
[F2][F8]2026-03-03−23,544→ 70,634 total→ Class A Common Stock (23,544 underlying) - Exercise/Conversion
Performance-Based Restricted Stock Units
[F4]2026-03-03−366,972→ 0 total→ Class A Common Stock (366,972 underlying) - Exercise/Conversion
Restricted Stock Units
[F2][F9]2026-03-04−35,880→ 71,760 total→ Class A Common Stock (35,880 underlying)
Footnotes (9)
- [F1]Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.
- [F2]Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
- [F3]Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.
- [F4]Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5.
- [F5]Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of performance-based restricted stock units.
- [F6]On March 3, 2022, the reporting person was granted 144,928 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
- [F7]On March 3, 2023, the reporting person was granted 183,486 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
- [F8]On March 3, 2025, the reporting person was granted 94,178 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
- [F9]On March 4, 2024, the reporting person was granted 143,519 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
Signature
/s/ Denis Butkovic, Attorney-in-Fact|2026-03-05